GlassScriptPhysician profile
Donny L Reeves
NPI 1558390385
$5,811.40
in general payments reported to CMS, 2019-2025
29 companies · $1,223 in 2025
The $1,223 reported for 2025 was more than what 82% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $462 · 2020: $332 · 2021: $694 · 2022: $647 · 2023: $571 · 2024: $1,884 · 2025: $1,223.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,677.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,677.37 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $818.42 | 2019-2025 | Clareon, Rocklatan, Unity |
| Lumenis Be INC | $796.28 | 2024 | Optilight |
| Johnson & Johnson Surgical Vision, INC. | $633.48 | 2019-2025 | Veritas Vision System, Tecnis Iol, Tecnis Simplicity |
| Mallinckrodt Hospital Products INC. | $470.26 | 2021-2025 | Acthar |
| Abbvie INC. | $343.40 | 2022-2025 | |
| Rxsight INC | $302.37 | 2023-2025 | Rxsight Injector Handpiece, Rxsight Contact Lens, Rxsight Light Delivery Device (Ldd) |
| Horizon Therapeutics Plc | $282.22 | 2020-2023 | Tepezza |
| Ivantis, INC | $276.04 | 2019-2020 | |
| Ocular Therapeutix, INC. | $207.99 | 2024-2025 | Dextenza |
| Allergan, INC. | $198.03 | 2019-2022 | |
| Eyepoint US, INC. | $159.67 | 2020-2021 | |
| Sun Pharmaceutical Industries INC. | $157.46 | 2019-2023 | Cequa |
| Oyster Point Pharma, INC. | $139.49 | 2022-2025 | Tyrvaya |
| Harrow Eye, LLC | $122.71 | 2023-2024 | Vevye, Iheezo |
| Vanda Pharmaceuticals INC. | $111.33 | 2020-2022 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $109.09 | 2022 | |
| Apellis Pharmaceuticals, INC. | $98.39 | 2023-2024 | Syfovre |
| Aerie Pharmaceuticals, INC. | $85.07 | 2019-2021 | |
| Genentech USA, INC. | $78.19 | 2023-2024 | Vabysmo |
| Tarsus Pharmaceuticals, INC. | $71.32 | 2024-2025 | Xdemvy |
| Sight Sciences, INC. | $63.99 | 2023-2025 | Omni Surgical System, Sion Surgical Instrument |
| Kala Pharmaceuticals, INC. | $57.53 | 2021-2022 | |
| Dompe US, INC. | $55.21 | 2024-2025 | Oxervate |
| Bausch & Lomb Americas INC. | $52.51 | 2023-2025 | Vyzulta, Miebo, Xiidra |
| Amgen INC. | $38.59 | 2024 | Tepezza |
| Lkc Technologies, INC. | $31.47 | 2025 | |
| Carl Zeiss Meditec Ag | $19.40 | 2020 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $17.46 | 2019 | |
| Biotissue Holdings INC. | $14.03 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Donny Reeves listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.